PT - JOURNAL ARTICLE AU - Leboyer, Marion AU - Foiselle, Marianne AU - Tchitchek, Nicolas AU - Tamouza, Ryad AU - Lorenzon, Roberta AU - Richard, Jean-Romain AU - Arrouasse, Raphaele AU - Le Corvoisier, Philippe AU - Le Dudal, Katia AU - Vicaut, Eric AU - Ellul, Pierre AU - Rosenzwajg, Michelle AU - Klatzmann, David TI - Low-dose interleukin-2 in patients with bipolar depression: a phase 2 randomised double-blind placebo-controlled trial AID - 10.1101/2024.07.19.24310686 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.19.24310686 4099 - http://medrxiv.org/content/early/2024/07/19/2024.07.19.24310686.short 4100 - http://medrxiv.org/content/early/2024/07/19/2024.07.19.24310686.full AB - Immune abnormalities including an insufficiency of regulatory T cells (Treg) and increased blood-based inflammatory markers have been observed in bipolar disorders (BD), particularly during depression. As Tregs are pivotal to control inflammation, Treg stimulation by low-dose IL-2 (IL-2LD) could have a therapeutic impact on bipolar depression. We performed a randomized, double-blind, placebo-controlled (2 active: 1 placebo) proof-of-concept trial of add-on IL-2LD in patients with bipolar depression. Patients received a placebo or IL-2LD (1MIU) once a day for 5 days, and then once a week for 4 weeks starting on week 2. The primary objective was to demonstrate a biological Treg response to IL-2LD assessed by fold increase in Treg percentage of CD4+ cells from baseline to day 5. Secondary objectives included safety assessment and mood improvement throughout the study period. This trial is registered with ClinicalTrials.gov, number NCT04133233. Fourteen patients with bipolar depression were included, with 4 receiving placebo and 10 IL-2LD. Baseline clinical and biological characteristics were balanced between groups. The primary evaluation criterion was met, with IL-2LD expanding 1.17 [95% CI 1.01-1.34] vs 1.01 [95% CI 0.90 - 1.12] (p=0.0421) and activating Tregs. Secondary evaluation criteria were also met with significant improvements of depressive symptoms and global functioning from day-15 onwards in the IL-2LD treated patients. The treatment was well-tolerated, with no serious adverse events related to treatment. This proof-of-concept trial shows that stimulating Tregs in patients with bipolar depression is safe and associated with clinical improvements. This supports a pathophysiological role of inflammation in BD and warrants pursuing the evaluation of IL-2LD as an adjunct treatment of major mood disorders.Competing Interest StatementMR, RL and DK are inventors for patent applications related to the therapeutic use of IL-2LD, which belongs to their academic institutions and has been licensed to ILTOO Pharma. MR and DK hold shares in ILTOO Pharma. No other potential conflicts of interest relevant to this article were reported.Clinical TrialNCT04133233Funding StatementThe research program on the effects of IL-2LD in depression was defined by ML and DK in 2017 as part of the H2020 MoodStratification proposal (Coordinator: H.Drexhage, 2018), and was later joined by Francesco Benedetti from Ospedale San Raffaele, Milan, Italy. We thank Hemo Drexhage and Francesco Benedetti for stimulating discussions. DEPIL-2 was primarily funded by MOODSTRATIFICATION. We thank ILTOO pharma for provided the study drugs. The immunomonitoring was supported by the ANR grant iMAP (ANR-16-RHUS-0001) to DK and ANR grant I-GIVE (ANR-13-SAMA-0004-01) to ML. The study was sponsored by Assistance Publique-Hopitaux de Paris, which had no role in the study design.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:DEPIL-2 was registered with EUDRACT number 2018-002777-22 and with ClinicalTrials number NCT04133233.The study was approved by the institutional review board of Hotel-Dieu Hospital in Paris and performed following the Declaration of Helsinki and good clinical practices. Written informed consent was obtained from all participants before enrolment in the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors